Navigation Links
Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Date:4/24/2008

- HspE7 Phase 2 Trial for Cervical Dysplasia to Begin Mid-2008 -

SAN DIEGO, April 24 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of the fourth and final cohort of patients in its Phase 1 clinical trial of HspE7, its lead therapeutic candidate, in women with cervical intraepithelial neoplasia (CIN). Findings from the fourth cohort safety review demonstrated that HspE7 was safe and well tolerated with no serious adverse events being reported.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

An evaluation by the Safety Review Committee was performed after each of the four cohorts reached five weeks of treatment (two doses plus one week of follow-up). All of the patients in the Phase 1 study were administered 500 mcg of HspE7 with each of the four cohorts receiving escalating doses of adjuvant -- 50, 500, 1,000 and 2,000 mcg. The company previously announced that HspE7 was also well tolerated in the first three cohorts.

In addition to safety data, immunological data were collected from all patients pre-treatment, following each dose of HspE7 and at the end of the study. Preliminary evaluation of biological samples collected from the study's first and second cohorts indicates that administration of HspE7 results in an E7-specific T-cell immune response. Independent research findings published by Jeffrey Weber, M.D., Ph.D., in the journal Gynecologic Oncology demonstrate that such an immune response may be associated with objective clinical responses in patients with CIN. Therefore, Nventa believes that HspE7 may successfully treat CIN by activating and enhancing the body's natural immune system. The company expects to release immunological data from the third and fourth cohorts in the coming months.

"We are pleased with the broa
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
4. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
5. Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
6. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
7. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
8. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
9. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
10. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
11. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Research and Markets has announced the addition ... Pipeline Insight 2014" report to their offering. ... eradicate the prevalence of cancer have achieved limited success ... specificity, safety and large number of side effects, which ... It has been discovered that peptides can be used ...
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... , June 26, 2010 Amylin Pharmaceuticals, ... Company (NYSE: LLY ) today announced results ... with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) ... the pancreas that produce insulin.) Three years of BYETTA ...
... ORLANDO, Fla. , June 26, 2010 ... Lilly and Company (NYSE: LLY ) and ... of an analysis of pooled safety data from three ... BYDUREON™ (exenatide extended-release for injectable suspension), dosed once weekly, ...
Cached Medicine Technology:Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 2Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 3Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 4Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 5Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 6Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 7Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010 8BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 2BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 3BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 4BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 5BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 6BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 7BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 8BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010 9
(Date:9/1/2014)... The National Association of Hispanic Nurses ( ... DNP, MPH, RN, and Adriana Perez, PhD, Rn, ANP-BC, ... Nursing. They will be inducted with Immediate Past President ... we reported last May. , Our three members will ... American Academy of Nursing Policy Conference in Washington, DC. ...
(Date:9/1/2014)... 2014 Bioinformatics refers to an ... biological and genetic data. A major part of ... software tools to generate and process useful biological ... biological computation. While bioinformatics simply makes use of ... its related concepts, biological computation refers to the ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many web hosting ... Top10BestSEOHosting.com is here to announce that JustHost, Bluehost ... in 2014. , JustHost ( http://www.justhost.com/track/seohosts ) provides ... hosting plan. The company’s approach to hosting is ... accessible and powerful enough for anyone to use. ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... Dec. 19 House Republican Whip,Roy Blunt (Mo.) issued ... funding under the State Children,s Health Insurance,Program (SCHIP) through ... days of the first session of the 110th,Congress, the ... for months - a proposal to extend the current ...
... IDEXX Laboratories,Inc. (Nasdaq: IDXX ), announced today ... Conference. Jonathan W. Ayers, Chairman,President and CEO, is scheduled ... 7, 2008 at 8:00 a.m. (PT), at the Westin ... live audio webcast of,the presentation through a link on ...
... Stronger National,Measures, Urges America,s Health Insurance Plan Proposal ... The National Patient,Advocate Foundation (NPAF) -- a national, ... to health care through state and,federal public policy ... today in its Individual Market Guarantee Access,Proposal that ...
... introduce NutreStore(TM) in spring 2008, TORRANCE, ... a,Torrance, California based pharmaceutical company, announced today ... agreement with Cato BioVentures of,Research Triangle Park, ... brand L-Glutamine. Under this agreement, Emmaus will,commercialize ...
... happiness and sadness. Although lost opportunities and mistaken expectations ... experiences may impact personality development and overall happiness. A ... the University of Missouri, indicates that individuals who take ... more likely to mature and achieve a potentially more ...
... in tumor-suppressing gene could point to lymph node involvement, ... Supposedly "innocent" cells in the area surrounding cancerous tumors ... can predict whether or not the cancer spreads to ... of alterations in the tumor-suppressing p53 gene in the ...
Cached Medicine News:Health News:Leading National Patient Advocacy Group Commends Insurance Industry's Recognition, Focus on Growing National Problem of Uninsured and Underinsured Americans 2Health News:Leading National Patient Advocacy Group Commends Insurance Industry's Recognition, Focus on Growing National Problem of Uninsured and Underinsured Americans 3Health News:Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome 2Health News:Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome 3Health News:What's the rush? Taking time to acknowledge loss is not that bad 2Health News:Area Around Breast Tumor May Predict Cancer's Spread 2Health News:Area Around Breast Tumor May Predict Cancer's Spread 3
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
The PerkinElmer LS 45 Luminescence spectrometer offers versatility, reliability and ease-of-use for routine analyses in an affordable package....
Medicine Products: